Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT02964910 Completed - Hepatitis E Clinical Trials

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )

Start date: August 2016
Phase: Phase 4
Study type: Interventional

This phase IV clinical study was designed to evaluate the immunogenicity and safety of Hecolin® in the chronic Hepatitis B patients on the clinical stability.

NCT ID: NCT02964091 Completed - Chronic Hepatitis C Clinical Trials

Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

SHARED
Start date: October 2016
Phase: Phase 4
Study type: Interventional

The main purpose of the study is to evaluate the efficacy, safety and tolerability of a medication, ledipasvir/sofosbuvir (LDV/SOF), used to treat individuals with chronic hepatitis C virus (HCV) in Rwandan adults. A sub-cohort of participants will have limited laboratory monitoring to determine the minimum laboratory tests necessary.

NCT ID: NCT02963714 Completed - Hepatitis B Vaccine Clinical Trials

Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients

Start date: December 2014
Phase: Phase 4
Study type: Interventional

Intramuscular injection of 40 μg hepatitis B vaccine in a standard three-dose schedule or a four-dose schedule is recommended for hemodialysis patients. However, seroconversion rates are inadequate and persistence of immunity remains a challenge. This is a randomized, controlled trial. The study will evaluate the immunogenicity, immune persistence, and safety of 20 µg and 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6 in hemodialysis patients.

NCT ID: NCT02960360 Not yet recruiting - Clinical trials for Chronic Delta Hepatitis

A Phase 2b Study of Lonafarnib With or Without Ritonavir in Patients With HDV

LOWR-5
Start date: March 2017
Phase: Phase 2
Study type: Interventional

A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus

NCT ID: NCT02959775 Completed - Clinical trials for Hepatitis B Vaccination

Immunogenicity of Hepatitis B Vaccination Among Drug Users

Start date: August 2014
Phase: Phase 4
Study type: Interventional

Uptake, adherence, and completion of vaccination among drug users were low, and their immune function and immune response to hepatitis B vaccination were also suboptimal, indicating that the current practice of hepatitis B vaccination can't protect drug users from HBV infection. This is a randomized, open-label, blank-controlled trial, conducted among drug users with drug rehabilitation. This study will compare the immunogenicity and safety of three intramuscular 20µg and 60µg recombinant hepatitis B vaccines at months 0, 1, and 6 among drug users

NCT ID: NCT02959684 Recruiting - HIV Clinical Trials

Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France

STRADA
Start date: April 14, 2017
Phase:
Study type: Observational

To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for HIV and hepatitis) amongst a population of legal migrants during their mandatory medical check-up. This study aims for a global improvement of screening and care for migrants.

NCT ID: NCT02957994 Active, not recruiting - Hepatitis B Clinical Trials

TAF Switch Study in Hepatitis B Monoinfection

Start date: December 22, 2016
Phase: Phase 4
Study type: Interventional

To evaluate various markers of renal function and bone density after the switch to Tenofovir alafenamide fumarate (TAF) in chronic hepatitis B patients who are currently treated with Tenofovir disoproxil fumarate (TDF) .

NCT ID: NCT02956850 Completed - Clinical trials for Hepatitis B, Chronic

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

Start date: December 12, 2016
Phase: Phase 1
Study type: Interventional

This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic hepatitis B. Part I will be conducted in two portions: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) which will include only healthy volunteers. Part II will commence after completion of the MAD portion of Part I and will include only Chronic Hepatitis B (CHB) participants.

NCT ID: NCT02956629 Terminated - Hepatitis C Clinical Trials

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

Start date: November 16, 2016
Phase: Phase 2
Study type: Interventional

This is a nonrandomized, multi-site, open-label trial to evaluate a novel two-drug combination regimen (uprifosbuvir [MK-3682] 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for 12 weeks) in male and female treatment-naïve (TN) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.

NCT ID: NCT02952924 Completed - Clinical trials for Hepatitis B, Chronic

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

Start date: December 14, 2016
Phase: Phase 1
Study type: Interventional

This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7049389 following oral administration in healthy volunteers and chronic HBV infected participants. Part 3 is a non-randomized, non-controlled, open-label part to assess the efficacy and safety of RO7049389 when administered in combination with standard-of-care therapies for up to 48 weeks in nucleos(t)ide (NUC)-suppressed and treatment-naive chronic hepatitis B (CHB) participants.